vs
Prestige Consumer Healthcare Inc.（PBH）与RBC Bearings INC（RBC）财务数据对比。点击上方公司名可切换其他公司
RBC Bearings INC的季度营收约是Prestige Consumer Healthcare Inc.的1.6倍（$461.6M vs $283.4M），Prestige Consumer Healthcare Inc.净利率更高（16.5% vs 14.6%，领先1.9%），RBC Bearings INC同比增速更快（17.0% vs -2.4%），RBC Bearings INC自由现金流更多（$99.1M vs $75.3M），过去两年RBC Bearings INC的营收复合增速更高（5.6% vs 1.2%）
Prestige Consumer Healthcare Inc.是一家美国企业，主营非处方健康护理产品及家用清洁产品的营销与分销业务。该公司于1996年由Medtech Products、Prestige Brands International及Spic and Span三家公司合并成立，总部位于纽约州塔里敦，在弗吉尼亚州林奇堡设有生产工厂。
该文本实际介绍的并非RBC Bearings，而是美国多佛公司。多佛是一家工业产品综合制造商，1955年成立，总部位于伊利诺伊州当纳斯格罗夫。2021年其业务分为五大板块：工程产品、清洁能源与加注、成像与识别、泵与工艺解决方案、气候与可持续技术，是标普500成分股，在纽约证券交易所上市。
PBH vs RBC — 直观对比
损益表 — Q3 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $283.4M | $461.6M |
| 净利润 | $46.7M | $67.4M |
| 毛利率 | 55.5% | 44.3% |
| 营业利润率 | 29.1% | 22.3% |
| 净利率 | 16.5% | 14.6% |
| 营收同比 | -2.4% | 17.0% |
| 净利润同比 | -23.5% | 16.4% |
| 每股收益（稀释后） | $0.97 | $2.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $283.4M | $461.6M | ||
| Q3 25 | $274.1M | $455.3M | ||
| Q2 25 | $249.5M | $436.0M | ||
| Q1 25 | $296.5M | $437.7M | ||
| Q4 24 | $290.3M | $394.4M | ||
| Q3 24 | $283.8M | $397.9M | ||
| Q2 24 | $267.1M | $406.3M | ||
| Q1 24 | $277.0M | $413.7M |
| Q4 25 | $46.7M | $67.4M | ||
| Q3 25 | $42.2M | $60.0M | ||
| Q2 25 | $47.5M | $68.5M | ||
| Q1 25 | $50.1M | $72.7M | ||
| Q4 24 | $61.0M | $57.9M | ||
| Q3 24 | $54.4M | $54.2M | ||
| Q2 24 | $49.1M | $61.4M | ||
| Q1 24 | $49.5M | — |
| Q4 25 | 55.5% | 44.3% | ||
| Q3 25 | 55.3% | 44.1% | ||
| Q2 25 | 56.2% | 44.8% | ||
| Q1 25 | 57.3% | 44.2% | ||
| Q4 24 | 55.5% | 44.3% | ||
| Q3 24 | 55.5% | 43.7% | ||
| Q2 24 | 54.7% | 45.3% | ||
| Q1 24 | 54.8% | 43.1% |
| Q4 25 | 29.1% | 22.3% | ||
| Q3 25 | 29.1% | 21.5% | ||
| Q2 25 | 28.8% | 23.2% | ||
| Q1 25 | 29.8% | 23.0% | ||
| Q4 24 | 31.7% | 21.7% | ||
| Q3 24 | 29.7% | 21.6% | ||
| Q2 24 | 27.0% | 24.0% | ||
| Q1 24 | 29.7% | 22.8% |
| Q4 25 | 16.5% | 14.6% | ||
| Q3 25 | 15.4% | 13.2% | ||
| Q2 25 | 19.0% | 15.7% | ||
| Q1 25 | 16.9% | 16.6% | ||
| Q4 24 | 21.0% | 14.7% | ||
| Q3 24 | 19.2% | 13.6% | ||
| Q2 24 | 18.4% | 15.1% | ||
| Q1 24 | 17.9% | — |
| Q4 25 | $0.97 | $2.13 | ||
| Q3 25 | $0.86 | $1.90 | ||
| Q2 25 | $0.95 | $2.17 | ||
| Q1 25 | $1.00 | $2.33 | ||
| Q4 24 | $1.22 | $1.82 | ||
| Q3 24 | $1.09 | $1.65 | ||
| Q2 24 | $0.98 | $1.90 | ||
| Q1 24 | $0.98 | $1.92 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $62.4M | $107.6M |
| 总债务越低越好 | $1.0B | $990.2M |
| 股东权益账面价值 | $1.8B | $3.3B |
| 总资产 | $3.5B | $5.1B |
| 负债/权益比越低杠杆越低 | 0.56× | 0.30× |
8季度趋势，按日历期对齐
| Q4 25 | $62.4M | $107.6M | ||
| Q3 25 | $119.1M | $91.2M | ||
| Q2 25 | $139.5M | $132.9M | ||
| Q1 25 | $97.9M | $36.8M | ||
| Q4 24 | $50.9M | — | ||
| Q3 24 | $51.5M | — | ||
| Q2 24 | $34.3M | $76.8M | ||
| Q1 24 | $46.5M | $63.5M |
| Q4 25 | $1.0B | $990.2M | ||
| Q3 25 | $993.1M | $1.1B | ||
| Q2 25 | $992.7M | $915.6M | ||
| Q1 25 | $992.4M | $920.1M | ||
| Q4 24 | $992.0M | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $1.1B | $1.2B |
| Q4 25 | $1.8B | $3.3B | ||
| Q3 25 | $1.8B | $3.2B | ||
| Q2 25 | $1.9B | $3.1B | ||
| Q1 25 | $1.8B | $3.0B | ||
| Q4 24 | $1.8B | $2.9B | ||
| Q3 24 | $1.7B | $2.9B | ||
| Q2 24 | $1.7B | $2.8B | ||
| Q1 24 | $1.7B | $2.8B |
| Q4 25 | $3.5B | $5.1B | ||
| Q3 25 | $3.4B | $5.1B | ||
| Q2 25 | $3.4B | $4.8B | ||
| Q1 25 | $3.4B | $4.7B | ||
| Q4 24 | $3.3B | $4.7B | ||
| Q3 24 | $3.3B | $4.7B | ||
| Q2 24 | $3.3B | $4.7B | ||
| Q1 24 | $3.3B | $4.7B |
| Q4 25 | 0.56× | 0.30× | ||
| Q3 25 | 0.54× | 0.34× | ||
| Q2 25 | 0.54× | 0.29× | ||
| Q1 25 | 0.54× | 0.30× | ||
| Q4 24 | 0.55× | — | ||
| Q3 24 | 0.61× | — | ||
| Q2 24 | 0.65× | — | ||
| Q1 24 | 0.68× | 0.43× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $78.3M | $122.1M |
| 自由现金流经营现金流 - 资本支出 | $75.3M | $99.1M |
| 自由现金流率自由现金流/营收 | 26.6% | 21.5% |
| 资本支出强度资本支出/营收 | 1.1% | 5.0% |
| 现金转化率经营现金流/净利润 | 1.68× | 1.81× |
| 过去12个月自由现金流最近4个季度 | $267.2M | — |
8季度趋势，按日历期对齐
| Q4 25 | $78.3M | $122.1M | ||
| Q3 25 | $57.5M | $88.4M | ||
| Q2 25 | $79.0M | $120.0M | ||
| Q1 25 | $61.8M | — | ||
| Q4 24 | $65.1M | $84.0M | ||
| Q3 24 | $69.8M | — | ||
| Q2 24 | $54.8M | $97.4M | ||
| Q1 24 | $66.9M | — |
| Q4 25 | $75.3M | $99.1M | ||
| Q3 25 | $55.4M | $71.7M | ||
| Q2 25 | $78.2M | $104.3M | ||
| Q1 25 | $58.4M | — | ||
| Q4 24 | $63.5M | $73.6M | ||
| Q3 24 | $67.8M | — | ||
| Q2 24 | $53.6M | $88.4M | ||
| Q1 24 | $63.8M | — |
| Q4 25 | 26.6% | 21.5% | ||
| Q3 25 | 20.2% | 15.7% | ||
| Q2 25 | 31.3% | 23.9% | ||
| Q1 25 | 19.7% | — | ||
| Q4 24 | 21.9% | 18.7% | ||
| Q3 24 | 23.9% | — | ||
| Q2 24 | 20.1% | 21.8% | ||
| Q1 24 | 23.0% | — |
| Q4 25 | 1.1% | 5.0% | ||
| Q3 25 | 0.8% | 3.7% | ||
| Q2 25 | 0.3% | 3.6% | ||
| Q1 25 | 1.2% | 3.2% | ||
| Q4 24 | 0.5% | 2.6% | ||
| Q3 24 | 0.7% | 4.1% | ||
| Q2 24 | 0.4% | 2.2% | ||
| Q1 24 | 1.1% | — |
| Q4 25 | 1.68× | 1.81× | ||
| Q3 25 | 1.36× | 1.47× | ||
| Q2 25 | 1.66× | 1.75× | ||
| Q1 25 | 1.23× | — | ||
| Q4 24 | 1.07× | 1.45× | ||
| Q3 24 | 1.28× | — | ||
| Q2 24 | 1.12× | 1.59× | ||
| Q1 24 | 1.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
RBC
| Domestic | $413.3M | 90% |
| Foreign | $48.3M | 10% |
